CS Tumor Size CS Extension CS Tumor Size/Ext Eval CS Lymph Nodes CS Lymph Nodes Eval Reg LN Pos Reg LN Exam CS Mets at DX CS Mets Eval

Size: px
Start display at page:

Download "CS Tumor Size CS Extension CS Tumor Size/Ext Eval CS Lymph Nodes CS Lymph Nodes Eval Reg LN Pos Reg LN Exam CS Mets at DX CS Mets Eval"

Transcription

1 Lip, Upper Lip (Vermilion or Labial Muosa) C00.0, C00.3 C00.0 External upper lip C00.3 Muosa of upper lip Note: AJCC inludes labial muosa (C00.3) with bual muosa (C06.0) CS Tumor Size CS Extension CS Tumor Size/Ext Eval CS Lymph Nodes CS Lymph Nodes Eval Reg LN Pos Reg LN Exam CS Mets at DX CS Mets Eval CS Site-Speifi Fator 1 Size of Lymph Nodes CS Site-Speifi Fator 2 OBSOLETE - Extraapsular Extension, Lymph Nodes for Head and Nek CS Site-Speifi Fator 3 Levels I-III, Lymph Nodes for Head and Nek CS Site-Speifi Fator 4 Levels IV-V and Retropharyngeal Lymph Nodes for Head and Nek CS Site-Speifi Fator 5 Levels VI-VII and Faial Lymph Nodes for Head and Nek CS Site-Speifi Fator 6 Parapharyngeal, Parotid, and Suboipital/Retroauriular Lymph Nodes, Lymph Nodes for Head and Nek CS Site-Speifi Fator 7 Upper and Lower Cervial Node Levels CS Site-Speifi Fator 8 Extraapsular Extension Clinially, Lymph Nodes for Head and Nek CS Site-Speifi Fator 9 Extraapsular Extension Pathologially, Lymph Nodes for Head and Nek CS Site-Speifi Fator 10 HPV (Human Papilloma Virus) Status CS Site-Speifi Fator 11 Measured Thikness (Depth) CS Site-Speifi Fator 12 CS Site-Speifi Fator 13 CS Site-Speifi Fator 14 CS Site-Speifi Fator 15 CS Site-Speifi Fator 16 CS Site-Speifi Fator 17 CS Site-Speifi Fator 18 CS Site-Speifi Fator 19 CS Site-Speifi Fator 20 CS Site-Speifi Fator 21 CS Site-Speifi Fator 22 CS Site-Speifi Fator 23 CS Site-Speifi Fator 24 CS Site-Speifi Fator 25 The following tables are available at the ollaborative staging website: Histology Inlusion Table AJCC 7th ed. Histology Exlusion Table AJCC 6th ed. AJCC TNM 7 Stage AJCC TNM 6 Stage Summary Stage Extension Size Table Lymph Nodes Size Table 29 April 2010 Part II - Lip - 1 Version

2 Lip, Upper CS Tumor Size (Revised: 10/18/2009) Note 1: the speifi tumor size as stated in the medial reord. Use ode 992, 994, or 995 if the physiian's statement about T value is the ONLY information available about the size of the tumor. (Refer to the CS Extension table for instrutions on oding extension.) 000 No mass/tumor found millimeters (ode exat size in millimeters) millimeters or larger 990 Mirosopi fous or foi only, no size of fous given 991 Desribed as "less than 1 m" 992 Desribed as "less than 2 m," or "greater than 1 m," or "between 1 m and 2 m" Stated as T1 with no other information on size 993 Desribed as "less than 3 m," or "greater than 2 m," or "between 2 m and 3 m" 994 Desribed as "less than 4 m," or "greater than 3 m," or "between 3 m and 4 m" Stated as T2 with no other information on size 995 Desribed as "less than 5 m," or "greater than 4 m," or "between 4 m and 5 m" Stated as T3 with no other information on size 996 Desribed as "greater than 5m" 999 Unknown; size not stated Lip, Upper CS Extension (Revised: 10/23/2009) Note 1: Periosteum is a fibrous membrane that wraps the outer surfae of bones. Cortial bone is the dense ompat outer layer of bone. Trabeular, anellous, or spongy bone (spongiosa) is a porous network of tissue filling the interior of bone, dereasing weight and allowing room for blood vessels and marrow. Note 2: AJCC assigns T value based on size when bone involvement is limited to the ortex. Involvement through ortial bone is required for assignment of T4a. Note 2: Use ode 300 for loalized tumor ONLY if no information is available to assign odes 100, 200, 405, 410, or 415. Note 3: Use ode 405, 410, 415, 778, 810, or 815 if the physiian's assignment of T ategory is the ONLY information available for the extent of the tumor. TNM 7 TNM 6 SS77 SS In situ; noninvasive; intraepithelial Tis Tis IS IS 29 April 2010 Part II - Lip - 2 Version

3 TNM 7 TNM 6 SS77 SS Invasive tumor onfined to: Labial muosa (inner lip) Lamina propria Multiple foi Submuosa (superfiial invasion) Vermilion surfae Superfiial extension to: Skin of lip Subutaneous soft tissue of lip ^ * L L 200 Musulature ^ * L L 300 Loalized, NOS ^ * L L 405 Stated as T1 with no other information on extension ^ * L L 410 Stated as T2 with no other information on extension ^ * L L 415 Stated as T3 with no other information on extension ^ * L L 500 Bual muosa (inner heek) Commissure Opposite (both) lip(s) 510 Upper gingiva Gingiva, NOS (Note: Lower gingiva moved to ode 780) 535 Cortial bone of maxilla Cortial bone NOS (not speified in higher odes) Bone, NOS (not speified in higher odes) 700 OBSOLETE DATA RETAINED V0200 Maxilla ^ * RE RE ^ * RE RE ^ * RE RE ERROR T4a RE RE 725 Trabeular bone of maxilla T4a T4a RE RE 740 Nose T4a T4a RE D 750 Tongue T4a T4a D D 760 Skin of fae/nek T4a T4a D D 770 OBSOLETE DATA RETAINED V0200 ERROR T4a D D Cortial bone (other than ode 700) Floor of mouth Inferior alveolar nerve 775 Floor of mouth Inferior alveolar nerve T4a T4a D D 778 Stated as T4a with no other information on extension T4a T4a RE RE 780 Lower gingiva T4b T4b D RE 29 April 2010 Part II - Lip - 3 Version

4 TNM 7 TNM 6 SS77 SS (740, 750, 760, or 775) T4b T4b D D (Lower gingiva + any struture in 740, 750, 760, or 775) 788 Bone of mandible Mandible NOS Speified bone (Other than maxilla, mandible, and bones in odes 790 and 800) 790 Mastiator spae Pterygoid plates 800 Further ontiguous extension inluding: T4b T4b D D T4b T4b D D T4b T4b D D Skull base Internal arotid artery (enased) 810 Stated as T4b with no other information on extension T4b T4b D D 815 Stated as T4 [NOS] with no other information on extension T4NOS T4NOS RE RE 950 No evidene of primary tumor T0 T0 U U 999 Unknown extension Primary tumor annot be assessed TX TX U U ^ For Extension odes 100 through 535 ONLY, the T ategory for AJCC 7th Edition staging is assigned based on the value of CS Tumor Size, as shown in the Extension Size Table for this site. * For Extension odes 100 through 535 ONLY, the T ategory for AJCC 6th Edition staging is assigned based on the value of CS Tumor Size, as shown in the Extension Size Table for this site. Lip, Upper CS Tumor Size/Ext Eval (Revised: 08/10/2009) Staging Basis 0 Does not meet riteria for AJCC pathologi staging: No surgial resetion done. Evaluation based on physial examination, imaging examination, or other non-invasive linial evidene. No autopsy evidene used. 1 Does not meet riteria for AJCC pathologi staging: No surgial resetion done. Evaluation based on endosopi examination, diagnosti biopsy, inluding fine needle aspiration biopsy, or other invasive tehniques, inluding surgial observation without biopsy. No autopsy evidene used. 29 April 2010 Part II - Lip - 4 Version

5 Staging Basis 2 Meets riteria for AJCC pathologi staging: p No surgial resetion done, but evidene derived from autopsy (tumor was suspeted or diagnosed prior to autopsy) 3 Either riteria meets AJCC pathologi staging: p Surgial resetion performed WITHOUT pre-surgial systemi treatment or radiation OR surgial resetion performed, unknown if pre-surgial systemi treatment or radiation performed AND Evaluation based on evidene aquired before treatment, supplemented or modified by the additional evidene aquired during and from surgery, partiularly from pathologi examination of the reseted speimen. No surgial resetion done. Evaluation based on positive biopsy of highest T lassifiation. 5 Does not meet riteria for AJCC y-pathologi (yp) staging: Surgial resetion performed AFTER neoadjuvant therapy and tumor size/extension based on linial evidene, unless the pathologi evidene at surgery (AFTER neoadjuvant) is more extensive (see ode 6). 6 Meets riteria for AJCC y-pathologi (yp) staging: yp Surgial resetion performed AFTER neoadjuvant therapy AND tumor size/extension based on pathologi evidene, beause pathologi evidene at surgery is more extensive than linial evidene before treatment. 8 Meets riteria for autopsy (a) staging: a Evidene from autopsy only (tumor was unsuspeted or undiagnosed prior to autopsy) 9 Unknown if surgial resetion done Not assessed; annot be assessed Unknown if assessed 29 April 2010 Part II - Lip - 5 Version

6 Lip, Upper CS Lymph Nodes (Revised: 01/25/2010) Note 1: For head and nek shemas, this field inludes all lymph nodes defined as Levels I-VII and Other by AJCC. The omplete definitions are provided in the General Instrutions. Note 2: For head and nek shemas, additional information about lymph nodes (size of involved nodes, extraapsular extension, levels involved, and loation of involved nodes above or below the lower border of the rioid artilage) is oded in Site-Speifi Fators 1, 3-9. Note 3: If laterality of lymph nodes is not speified, assume nodes are ipsilateral. Midline nodes are onsidered ipsilateral. Note 4: For head and nek aners, if lymph nodes are desribed only as "supralaviular", try to determine if they are in Level IV (deep to the sternoleidomastoid musle, in the lower jugular hain) or Level V (in the posterior triangle, inferior to the transverse ervial artery) and ode appropriately. If the speifi level annot be determined, onsider them as Level V nodes. Note 5: The desription of lymph nodes has been standardized aross the head and nek shemas. All lymph node levels and groups listed here are onsidered regional nodes for AJCC staging. Summary Stage 1977 and Summary Stage 2000 divide these nodes into regional and distant groups. Note 6: Level I nodes moved from ode 110 in CSv1 to ode 105. TNM 7 TNM 6 SS77 SS None; no regional lymph node involvement N0 N0 NONE NONE 100 Single positive ipsilateral regional node: Other groups: Faial: Buinator (bual) Nasolabial Parotid Infraauriular Intraparotid Periparotid Preauriular Regional lymph node, NOS 105 Single positive ipsilateral regional node: Level 1A Submental Level IB Submandibular (submaxillary) 110 Single positive ipsilateral regional node: Level II node - Upper jugular Jugulodigastri (subdigastri) Upper deep ervial Level IIA Level IIB Level III node - Middle jugular Middle deep ervial Level IV node - Lower jugular Jugulo-omohyoid (supraomohyoid) Lower deep ervial Virhow node Cervial, NOS Deep ervial, NOS Internal jugular, NOS ^ * RN RN ^ * RN D ^ * D RN 29 April 2010 Part II - Lip - 6 Version

7 TNM 7 TNM 6 SS77 SS Single positive ipsilateral regional node: Level V node Posterior triangle group Posterior ervial Level VA - Spinal aessory Level VB - Transverse ervial, supralaviular Level VI node - Anterior ompartment group Laterotraheal Paralaryngeal Paratraheal - above suprasternal noth Perithyroidal Prerioid (Delphian) Prelaryngeal Pretraheal - above suprasternal noth Reurrent laryngeal Level VII node - Superior mediastinal group (for other mediastinal nodes see CS Mets at DX) Esophageal groove Paratraheal - below suprasternal noth Pretraheal - below suprasternal noth Other groups: Faial: Mandibular Parapharyngeal Retroauriular Retropharyngeal Sublingual Suboipital ^ * D D 180 Stated as N1, no other information N1 N1 RN RN 190 Stated as N2a, no other information N2a N2a RN RN 200 Multiple positive ipsilateral nodes listed in ode 100 ^ * RN RN 205 Multiple positive ipsilateral nodes, any listed in ode 105 (WITH or WITHOUT nodes listed in ode 100) 210 Multiple positive ipsilateral nodes, any listed in ode 110 (WITH or WITHOUT nodes listed in ode 100) 215 Multiple positive ipsilateral nodes listed in both odes 105 and 110 (WITH or WITHOUT nodes listed in ode 100) 220 Multiple positive ipsilateral nodes, any listed in ode 120 (WITH or WITHOUT nodes listed in ode 100, 105, or 110) ^ * RN D ^ * D RN ^ * D D ^ * D D 290 Stated as N2b, no other information N2b N2b RN RN 29 April 2010 Part II - Lip - 7 Version

8 TNM 7 TNM 6 SS77 SS Regional lymph nodes listed in ode 100: Positive ipsilateral node(s), not stated if single or multiple 305 Regional lymph nodes listed in ode 105: Positive ipsilateral node(s), not stated if single or multiple 310 Regional lymph nodes listed in ode 110: Positive ipsilateral node(s), not stated if single or multiple 320 Regional lymph nodes listed in ode 120: Positive ipsilateral node(s), not stated if single or multiple 400 Regional lymph nodes listed in ode 100: Positive bilateral or ontralateral nodes 405 Regional lymph nodes, any listed in ode 105: Positive bilateral or ontralateral nodes (WITH or WITHOUT nodes listed in ode 100) 410 Regional lymph nodes, any listed in ode 110: Positive bilateral or ontralateral nodes (WITH or WITHOUT nodes listed in ode 100) 415 Regional lymph nodes listed in both odes 105 and 110: Positive bilateral or ontralateral nodes (WITH or WITHOUT nodes listed in ode 100) 420 Regional lymph nodes, any listed in ode 120: Positive bilateral or ontralateral nodes (WITH or WITHOUT nodes listed in ode 100, 105, or 110) ^ * RN RN ^ * RN D ^ * D RN ^ * D D ^ * RN RN ^ * RN D ^ * D RN ^ * D D ^ * D D 490 Stated as N2, no other information N2 N2 RN RN 500 Regional lymph nodes listed in ode 100: Positive node(s), not stated if ipsilateral, or bilateral, or ontralateral, AND not stated if single or multiple 505 Regional lymph nodes listed in ode 105: Positive node(s), not stated if ipsilateral, or bilateral, or ontralateral, AND not stated if single or multiple 510 Regional lymph nodes listed in ode 110: Positive node(s), not stated if ipsilateral, or bilateral, or ontralateral, AND not stated if single or multiple 520 Regional lymph nodes as listed in ode 120: Positive node(s), not stated if ipsilateral, or bilateral, or ontralateral, AND not stated if single or multiple ^ * RN RN ^ * RN D ^ * D RN ^ * D D 29 April 2010 Part II - Lip - 8 Version

9 TNM 7 TNM 6 SS77 SS Stated as N2, NOS N2NOS N2NOS RN RN 700 Stated as N3, no other information N3 N3 RN RN 800 Lymph nodes, NOS, no other information ^ * RN RN 999 Unknown; not stated Regional lymph nodes annot be assessed NX NX U U ^ For odes , , , , , and 800 ONLY, the N ategory for AJCC 7th Edition staging is assigned based on the value of Site-Speifi Fator 1, Size of Lymph Nodes, using the extra table, Lymph Nodes Size Table, for this site. * For odes , , , , , and 800 ONLY, the N ategory for AJCC 6th Edition staging is assigned based on the value of Site-Speifi Fator 1, Size of Lymph Nodes, using the extra table, Lymph Nodes Size Table, for this site. Lip, Upper CS Lymph Nodes Eval (Revised: 10/26/2009) Note 1: This field is used primarily to derive the staging basis for the N ategory in the TNM system. It reords how the ode for the item "CS Lymph Nodes" was determined based on the diagnosti methods employed and their intent. Note 2: In the 7th edition of the AJCC manual, the linial and pathologi lassifiation rules for the N ategory were hanged to reflet urrent medial pratie. The N is designated as linial or pathologi based on the intent (workup versus treatment) mathing with the assessment of the T lassifiation. When the intent is workup, the staging basis is linial, and when the intent is treatment, the staging basis is pathologi. A. Mirosopi assessment inluding biopsy of regional nodes or sentinel nodes if being performed as part of the workup to hoose the treatment plan, is therefore part of the linial staging. When it is part of the workup, the T ategory is linial, and there has not been a resetion of the primary site adequate for pathologi T lassifiation (whih would be part of the treatment). B. Mirosopi assessment of regional nodes if being performed as part of the treatment is therefore part of the pathologi staging. When it is part of the treatment, the T ategory is pathologi, and there has been a resetion of the primary site adequate for pathologi T lassifiation (all part of the treatment). Note 3: Mirosopi assessment of the highest N ategory is always pathologi (ode 3). Note 4: If lymph node dissetion is not performed after neoadjuvant therapy, use ode 0 or 1. Note 5: Only odes 5 and 6 are used if the node assessment is performed after neoadjuvant therapy. Staging Basis 0 Does not meet riteria for AJCC pathologi staging: No regional lymph nodes removed for examination. Evidene based on physial examination, imaging examination, or other non-invasive linial evidene. No autopsy evidene used. 29 April 2010 Part II - Lip - 9 Version

10 Staging Basis 1 Does not meet riteria for AJCC pathologi staging based on at least one of the following riteria: No regional lymph nodes removed for examination. Evidene based on endosopi examination, or other invasive tehniques inluding surgial observation, without biopsy. No autopsy evidene used. OR Fine needle aspiration, inisional ore needle biopsy, or exisional biopsy of regional lymph nodes or sentinel nodes as part of the diagnosti workup, WITHOUT removal of the primary site adequate for pathologi T lassifiation (treatment). 2 Meets riteria for AJCC pathologi staging: p No regional lymph nodes removed for examination, but evidene derived from autopsy (tumor was suspeted or diagnosed prior to autopsy). 3 Meets riteria for AJCC pathologi staging based on at least one of the following riteria: p Any mirosopi assessment of regional nodes (inluding FNA, inisional ore needle bx, exisional bx, sentinel node bx or node resetion), WITH removal of the primary site adequate for pathologi T lassifiation (treatment) or biopsy assessment of the highest T ategory. OR Any mirosopi assessment of a regional node in the highest N ategory, regardless of the T ategory information. 5 Does not meet riteria for AJCC y-pathologi (yp) staging: Regional lymph nodes removed for examination AFTER neoadjuvant therapy AND lymph node evaluation based on linial evidene, unless the pathologi evidene at surgery (AFTER neoadjuvant) is more extensive (see ode 6). 6 Meets riteria for AJCC y-pathologi (yp) staging: yp Regional lymph nodes removed for examination AFTER neoadjuvant therapy AND lymph node evaluation based on pathologi evidene, beause the pathologi evidene at surgery is more extensive than linial evidene before treatment. 8 Meets riteria for AJCC autopsy (a) staging: a Evidene from autopsy; tumor was unsuspeted or undiagnosed prior to autopsy. 9 Unknown if lymph nodes removed for examination Not assessed; annot be assessed Unknown if assessed 29 April 2010 Part II - Lip - 10 Version

11 Lip, Upper Reg LN Pos (Revised: 03/30/2009) Note: Reord this field even if there has been preoperative treatment. 00 All nodes examined negative nodes positive (ode exat number of nodes positive) or more nodes positive 95 Positive aspiration or ore biopsy of lymph node(s) 97 Positive nodes - number unspeified 98 No nodes examined 99 Unknown if nodes are positive; not appliable Lip, Upper Reg LN Exam (Revised: 03/02/2009) 00 No nodes examined nodes examined (ode exat number of regional lymph nodes examined) or more nodes examined 95 No regional nodes removed, but aspiration or ore biopsy of regional nodes performed 96 Regional lymph node removal doumented as sampling and number of nodes unknown/not stated 97 Regional lymph node removal doumented as dissetion and number of nodes unknown/not stated 98 Regional lymph nodes surgially removed but number of lymph nodes unknown/not stated and not doumented as sampling or dissetion; nodes examined, but number unknown 99 Unknown if nodes were examined; not appliable or negative Lip, Upper CS Mets at DX (Revised: 07/23/2009) Note: Supralaviular and transverse ervial lymph nodes are oded in CS Lymph Nodes beause they are ategorized as N rather than M in AJCC TNM. TNM 7 TNM 6 SS77 SS No; none M0 M0 NONE NONE 10 Distant lymph node(s) Mediastinal Distant lymph node(s), NOS M1 M1 D D 29 April 2010 Part II - Lip - 11 Version

12 TNM 7 TNM 6 SS77 SS Distant metastases exept distant lymph node(s)(ode 10) Carinomatosis 50 (10) + (40) Distant lymph node(s) plus other distant metastases 60 Distant metastasis, NOS Stated as M1, NOS 99 Unknown if distant metastasis Distant metastasis annot be assessed M1 M1 D D M1 M1 D D M1 M1 D D M0 MX U U Lip, Upper CS Mets Eval (Revised: 08/10/2009) Note: This item reflets the validity of the lassifiation of the item CS Mets at DX only aording to the diagnosti methods employed. Staging Basis 0 Does not meet riteria for AJCC pathologi staging of distant metastasis: Evaluation of distant metastasis based on physial examination, imaging examination, and/or other non-invasive linial evidene. No pathologi examination of metastati tissue performed or pathologi examination was negative. 1 Does not meet riteria for AJCC pathologi staging of distant metastasis: Evaluation of distant metastasis based on endosopi examination or other invasive tehnique, inluding surgial observation without biopsy. No pathologi examination of metastati tissue performed or pathologi examination was negative. 2 Meets riteria for AJCC pathologi staging of distant metastasis: p No pathologi examination of metastati speimen done prior to death, but positive metastati evidene derived from autopsy (tumor was suspeted or diagnosed prior to autopsy). 3 Meets riteria for AJCC pathologi staging of distant metastasis: p Speimen from metastati site mirosopially positive WITHOUT pre-surgial systemi treatment or radiation OR speimen from metastati site mirosopially positive, unknown if pre-surgial systemi treatment or radiation performed OR speimen from metastati site mirosopially positive prior to neoadjuvant treatment. 5 Does not meet riteria for AJCC y-pathologi (yp) staging of distant metastasis: Speimen from metastati site mirosopially positive WITH pre-surgial systemi treatment or radiation, BUT metastasis based on linial evidene. 29 April 2010 Part II - Lip - 12 Version

13 Staging Basis 6 Meets riteria for AJCC y-pathologi (yp) staging of distant metastasis: Speimen from metastati site mirosopially positive WITH pre-surgial systemi treatment or radiation, BUT metastasis based on pathologi evidene. 8 Meets riteria for AJCC autopsy (a) staging of distant metastasis: yp a Evidene from autopsy based on examination of positive metastati tissue AND tumor was unsuspeted or undiagnosed prior to autopsy. 9 Not assessed; annot be assessed Unknown if assessed Lip, Upper CS Site-Speifi Fator 1 Size of Lymph Nodes (Revised: 12/01/2009) Note: the largest diameter, whether measured linially or pathologially, of any involved regional lymph node(s). Do not ode the size of any nodes oded in CS Mets at DX. 000 No involved regional nodes millimeters (ode exat size in millimeters) millimeters or larger OBSOLETE DATA CONVERTED V0200 See ode millimeters 989 OBSOLETE DATA CONVERTED V0200 See ode millimeters or larger 990 Mirosopi fous or foi only, no size of fous given 991 Desribed as "less than 1m" 992 Desribed as "less than 2m" or "greater than 1m" or "between 1m and 2m" 993 Desribed as "less than 3m" or "greater than 2m" or "between 2m and 3m" 994 Desribed as "less than 4m" or "greater than 3m" or "between 3m and 4m" 995 Desribed as "less than 5m" or "greater than 4m" or "between 4m and 5m" 996 Desribed as "less than 6m" or "greater than 5m" or "between 5m and 6m" 997 Desribed as "more than 6m" 29 April 2010 Part II - Lip - 13 Version

14 999 Regional lymph node(s) involved, size not stated Unknown if regional lymph node(s) involved Lip, Upper CS Site-Speifi Fator 2 OBSOLETE - Extraapsular Extension, Lymph Nodes for Head and Nek (Revised: 12/30/2009) Note 1: This CS Site-Speifi Fator is obsolete beginning with CS Version 2 (odes and notes). Old data are retained, but new ases are not oded with this Fator. Use ode 988 for this field. Note 2: the status of extraapsular extension whether assessed linially or pathologially of any involved regional lymph node(s) oded in the CS Lymph Nodes field. Do not ode extraapsular extension in any nodes oded in CS Mets at DX in this field. Note 3: A statement of the presene or absene of extraasular extension in a pathology report takes priority over linial assessment. However, if the pathology report ontains no statement about extraapsular extension, either positive or negative, the linial assessment should be oded. If nodes are involved but there is neither a linial assessment of extranodal extension nor a statement about it in the pathology report, use ode 999. Note 4: Aording to AJCC (page 24), "Imaging studies showing amorphous speulated margins of involved nodes or involvement of internodal fat resulting in loss of normal oval-to-round nodal shape strongly suggest extraapsular (extranodal) tumor spread; however, pathologi examination is neessary for doumentation of the extent of suh disease." Note 5: CS Site-Speifi Fator 2 is obsolete beginning with CS Version 2 (odes and notes). Old data are retained, but new ases are not oded with this Fator. Use ode 988 for this field. 000 OBSOLETE DATA RETAINED V0200 No extraapsular extension 001 OBSOLETE DATA RETAINED V0200 Extraapsular extension linially, not assessed pathologially Nodes desribed as "fixed", not assessed pathologially 005 OBSOLETE DATA RETAINED V0200 Extraapsular extension present pathologially 888 OBSOLETE DATA CONVERTED V0200 See ode 987 Not appliable; no lymph node involvement 987 OBSOLETE DATA CONVERTED AND RETAINED V0200 Data onverted from ode 888 Not appliable; no lymph node involvement 988 Not appliable: Information not olleted for this ase 999 OBSOLETE DATA RETAINED V0200 Unknown if regional lymph node(s) involved, not stated Regional lymph nodes annot be assessed 29 April 2010 Part II - Lip - 14 Version

15 Lip, Upper CS Site-Speifi Fator 3 Levels I-III, Lymph Nodes for Head and Nek (Revised: 03/30/2009) Note: Site-Speifi Fators 3-6 are used to ode the presene or absene of lymph node involvement in eah of 7 different levels and other groups defined by AJCC. The definitions of the levels are the same for all appliable head and nek sites. One digit is used to represent lymph nodes of a single level, with the three digits of Site-Speifi Fator 3 representing lymph nodes of, respetively, Levels I-III; the digits of Site-Speifi Fator 4 representing lymph nodes of Levels IV and V and the retropharyngeal nodes; the digits of Site-Speifi Fator 5 representing lymph nodes of Levels VI and VII and the faial nodes; and the digits of Site-Speifi Fator 6 representing the remaining Other groups as defined by AJCC. In eah digit, a ode 1 means Yes, the nodes are involved. 000 No lymph node involvement in Levels I, II, or III 100 Level I lymph node(s) involved 010 Level II lymph node(s) involved 001 Level III lymph node(s) involved 110 Level I and II lymph nodes involved 101 Level I and III lymph nodes involved 011 Level II and III lymph nodes involved 111 Level I, II and III lymph nodes involved 999 Unknown if regional lymph node(s) involved, not stated Regional lymph nodes annot be assessed Lip, Upper CS Site-Speifi Fator 4 Levels IV-V and Retropharyngeal Lymph Nodes for Head and Nek (Revised: 03/30/2009) Note: Site-Speifi Fators 3-6 are used to ode the presene or absene of lymph node involvement in eah of 7 different levels and other groups defined by AJCC. The definitions of the levels are the same for all appliable head and nek sites. One digit is used to represent lymph nodes of a single level, with the three digits of Site-Speifi Fator 3 representing lymph nodes of, respetively, Levels I-III; the digits of Site-Speifi Fator 4 representing lymph nodes of Levels IV and V and the retropharyngeal nodes; the digits of Site-Speifi Fator 5 representing lymph nodes of Levels VI and VII and the faial nodes; and the digits of Site-Speifi Fator 6 representing the remaining Other groups as defined by AJCC. In eah digit, a ode 1 means Yes, the nodes are involved. 000 No lymph node involvement in Levels IV or V or retropharyngeal 100 Level IV lymph node(s) involved 010 Level V lymph node(s) involved 001 Retropharyngeal nodes involved 110 Level IV and V lymph nodes involved 101 Level IV and retropharyngeal nodes involved 29 April 2010 Part II - Lip - 15 Version

16 011 Level V and retropharyngeal nodes involved 111 Level IV and V and retropharyngeal lymph nodes involved 999 Unknown if regional lymph node(s) involved, not stated Regional lymph nodes annot be assessed Lip, Upper CS Site-Speifi Fator 5 Levels VI-VII and Faial Lymph Nodes for Head and Nek (Revised: 03/30/2009) Note 1: Site-Speifi Fators 3-6 are used to ode the presene or absene of lymph node involvement in eah of 7 different levels and other groups defined by AJCC. The definitions of the levels are the same for all appliable head and nek sites. One digit is used to represent lymph nodes of a single level, with the three digits of Site-Speifi Fator 3 representing lymph nodes of, respetively, Levels I-III; the digits of Site-Speifi Fator 4 representing lymph nodes of Levels IV and V and the retropharyngeal nodes; the digits of Site-Speifi Fator 5 representing lymph nodes of Levels VI and VII and the faial nodes; and the digits of Site-Speifi Fator 6 representing the remaining Other groups as defined by AJCC. In eah digit, a ode 1 means Yes, the nodes are involved. Note 2: Faial nodes inluding buinator, mandibular, and nasolabial lymph nodes. 000 No lymph node involvement in Levels VI or VII or faial nodes 100 Level VI lymph node(s) involved 010 Level VII lymph node(s) involved 001 Faial lymph node(s) involved 110 Level VI and VII lymph nodes involved 101 Level VI and faial nodes involved 011 Level VII and faial nodes involved 111 Level VI and VII and faial lymph nodes involved 999 Unknown if regional lymph node(s) involved, not stated Regional lymph nodes annot be assessed 29 April 2010 Part II - Lip - 16 Version

17 Lip, Upper CS Site-Speifi Fator 6 Parapharyngeal, Parotid, and Suboipital/Retroauriular Lymph Nodes, Lymph Nodes for Head and Nek (Revised: 08/25/2009) Note: Site-Speifi Fators 3-6 are used to ode the presene or absene of lymph node involvement in eah of 7 different levels and other groups defined by AJCC. The definitions of the levels are the same for all appliable head and nek sites. One digit is used to represent lymph nodes of a single level, with the three digits of Site-Speifi Fator 3 representing lymph nodes of, respetively, Levels I-III; the digits of Site-Speifi Fator 4 representing lymph nodes of Levels IV and V and the retropharyngeal nodes; the digits of Site-Speifi Fator 5 representing lymph nodes of Levels VI and VII and the faial nodes; and the digits of Site-Speifi Fator 6 representing the remaining Other groups as defined by AJCC. In eah digit, a ode 1 means Yes, the nodes are involved. 000 No involvement of any group: Parapharyngeal lymph nodes Parotid (preauriular, periparotid, and/or intraparotid) lymph nodes Suboipital/retroauriular lymph nodes 100 Parapharyngeal lymph node(s) involved 010 Parotid (preauriular, periparotid, and/or intraparotid) lymph node(s) involved 001 Suboipital/retroauriular lymph node(s) involved 110 Involvement of two groups: Parapharyngeal lymph nodes Parotid (preauriular, periparotid, and/or intraparotid) lymph nodes 101 Involvement of two groups: Parapharyngeal lymph nodes Suboipital/retroauriular lymph nodes 011 Involvement of two groups: Parotid (preauriular, periparotid, and/or intraparotid) lymph nodes Suboipital lymph nodes 111 Involvement of three groups: Parapharyngeal lymph nodes Parotid (preauriular, periparotid, and/or intraparotid) lymph nodes, Suboipital/retroauriular lymph nodes 999 Unknown if regional lymph node(s) involved, not stated Regional lymph nodes annot be assessed 29 April 2010 Part II - Lip - 17 Version

18 Lip, Upper CS Site-Speifi Fator 7 Upper and Lower Cervial Node Levels (Revised: 03/30/2009) Note 1: AJCC requires that nodes be designated as involving upper or lower levels within the nek. The boundary between upper and lower levels is the lower border of the rioid artilage. Note 2: Nodes in Levels I, II, and III are upper level nodes. Nodes in Level IV and VII are lower level nodes. Level VA nodes are upper level nodes, and Level VB are lower level nodes. Level VI nodes span both upper and lower levels. Nodes inluded in "Other groups" (Faial, Parotid, Parapharyngeal, Retropharyngeal, Retroauriular, and Suboipital) are all upper level nodes. Note 3: the loation of nodal involvement in relation to the lower border of the rioid artilage of all involved nodes, whether assessed linially or pathologially, as stated by a physiian. Note 4: If there is no physiian statement of upper and/or lower level nodal involvement, assign levels I, II, III, and VA nodes to upper level. Assign level IV, VB, and VII to lower level. If Level V (A and B not speified) and/or Level VI nodes are involved with no further information about loation, use ode 040. Note 5: A desription of "mid nek" requires larifiation with the physiian. 040, unknown level, if "mid nek" is the only information available. 000 No lymph nodes involved 010 Upper level lymph nodes involved (all involved nodes above the lower border of the rioid artilage) 020 Lower level lymph nodes involved (all involved nodes below the lower border of the rioid artilage) 030 Upper and lower level lymph nodes involved (all involved nodes both above and below the lower border of the rioid artilage) 040 Unknown level lymph nodes involved (unable to determine if involved nodes above or below the lower border of the rioid artilage) 988 Not appliable: Information not olleted for this ase 999 Unknown if regional lymph node(s) involved, not stated Lip, Upper CS Site-Speifi Fator 8 Extraapsular Extension Clinially, Lymph Nodes for Head and Nek (Revised: 10/16/2009) Note 1: the status of extraapsular extension aessed linially for any involved regional lymph node(s) oded in the CS Lymph Nodes field. Do not ode extraapsular extensio in any nodes oded in CS Mets at DX in this field. Note 2: If nodes are involved linially, and doumentation of physial examination or imaging is available without a statement of extraapsular extension, use ode 010. Note 3: If the only doumentation is a referene to linially involved nodes with no referene to extraapsular extension, use ode 030. Note 4: If there is no information about linial assessment of nodes, use ode 999. Note 5: Clinial assessment an be by physial examination or imaging. Aording to AJCC, "ECS an be diagnosed linially by a matted mass of nodes adherent to overlying skin, adjaent soft tissue, or linial evidene of ranial nerve tissue. Radiologi signs of ECS inlude amorphous, spiulated margins of a metastati node and stranding of the perinodal soft tissue in previously untreated patients." 000 No lymph nodes involved linially 010 Nodes involved linially, no extraapsular extension linially 29 April 2010 Part II - Lip - 18 Version

19 020 Nodes involved linially, extraapsular extension linially (nodes desribed as fixed or matted) 030 Nodes involved linially, unknown if extraapsular extension 988 Not appliable: Information not olleted for this ase 997 Clinial examination of lymph nodes performed, unknown results 998 No linial examination of lymph nodes 999 Unknown if regional lymph node(s) involved linially, not stated Regional lymph nodes annot be aessed Lip, Upper CS Site-Speifi Fator 9 Extraapsular Extension Pathologially, Lymph Nodes for Head and Nek (Revised: 08/25/2009) Note 1: the status of extraapsular extension assessed pathologially of any involved regional lymph node(s) oded in the CS Lymph Nodes field. Do not ode extraapsular extension in any nodes oded in CS Mets at DX in this field. Note 2: If nodes are involved pathologially but there is no statement of extranodal extension in the pathology report, use ode 010. Note 3: "mirosopi" or "marosropi" extranodal extension as stated in the final diagnosis. If not stated in the final diagnosis, ode "mirosopi" if extranodal extension is desribed only in the mirosopi setion of the pathology report and "marosopi" if extranodal extension is desribed in the gross setion of the pathology report. Note 4: "Marosopi" extension takes priority over "mirosopi" extension. Note 5: Use ode 040 if pathologi extraapsular extension is desribed with no further information and the pathology report is not available for review. Note 6: Use ode 050 if nodes involved pathologially with no further information about extraapsular extension. 000 No lymph nodes involved pathologially 010 Nodes involved pathologially, no extraapsular extension pathologially 020 Nodes involved pathologially, MICROSCOPIC extraapsular extension pathologially 030 Nodes involved pathologially, MACROSCOPIC extraapsular extension pathologially 040 Nodes involved pathologially, extraapsular extension pathologially, unknown if mirosopi or marosopi 050 Nodes involved pathologially, unknown if extraapsular extension 988 Not appliable: Information not olleted for this ase 997 Pathologi examination of lymph nodes performed, results not available 998 No pathologi examination of lymph nodes 999 Unknown if regional lymph node(s) involved pathologially, not stated 29 April 2010 Part II - Lip - 19 Version

20 Lip, Upper CS Site-Speifi Fator 10 HPV (Human Papilloma Virus) Status (Revised: 10/12/2009) Note 1: There is evidene that human papilloma virus (HPV) plays a role in the pathogenesis of some aners. Note 2: Reord the results of any HPV testing performed on pathologi speimens from the primary tumor or a metastati site, inluding regional nodes. HPV testing may be performed for prognosti purposes; testing may also be performed on metastati sites to aid in the determination of the primary site. Note 3: The highest risk HPV types are types 16 and 18. Other high risk types are 31, 33, 35, 36, 45, 51, 52, 56, 58, 59, 68, 26, 53, 66, 67, 69, 70, 73, 82, 85 Low risk types are 6, 11, 32, 34, 40, 42, 44, 54, 61, 62, 64, 71, 72, 74, 81, 83, 84, 87, 89. The HPV vaine is designed to protet against types 16 and 18 (assoiated with ervial aner) and types 6 and 11 (assoiated with genital warts). Note 4: High risk may be abbreviated "hrhpv" or "HR-HPV". Note 5: Some tests for HPV, suh as a hybrid apture test, only report negative or positive for high risk HPV without identifying types; use odes 025 and 050, respetively to report those test results. 000 HPV test negative; not positive for any HPV types Negative, NOS 010 LOW RISK positive (all positive type(s) are low risk) 020 HIGH RISK positive, speified type(s) other than types 16 or 18, WITH or WITHOUT positive results for low risk type(s) 030 HIGH RISK positive for HPV 16 WITHOUT positive results for HPV 18 or positivity of HPV 18 unknown, WITH or WITHOUT positive results for other high-risk types, WITH or WITHOUT positive results for low risk type(s) 040 HIGH RISK positive for HPV 18 WITHOUT positive results for HPV 16 or positivity of HPV 16 unknown, WITH or WITHOUT positive results for other high-risk types, WITH or WITHOUT positive results for low risk type(s) 050 HIGH RISK positive for HPV 16 AND HPV 18, WITH or WITHOUT positive results for other high-risk types, WITH or WITHOUT positive results for low risk type(s) 060 HIGH RISK positive, NOS, type(s) not speified 070 Positive, NOS, risk and type(s) not stated 988 Not appliable: Information not olleted for this ase 997 Test ordered, results not in hart 998 Test not done (test was not ordered and was not performed), inluding no pathologi speimen available for HPV testing 999 Unknown or no information 29 April 2010 Part II - Lip - 20 Version

21 Lip, Upper CS Site-Speifi Fator 11 Measured Thikness (Depth) (Revised: 11/15/2009) Note 1: MEASURED THICKNESS (Depth) of the invasive tumor not size, diameter, or any other measurement. Reord the atual measurement in tenths of millimeters as stated on the pathology repot. Do not reord the measurement from a radiographi report. Note 2: Reord the measurement labeled speifially as thikness or depth of tumor. In the absene of a label,use the "ut surfae" dimension, or the third dimension from a desription of 3 dimensions (N1 x N2 x N3). For example, from a tumor size reorded as 2m x 1m x 0.5m, reord No mass/tumor found Exat thikness in tenths of millimeters Examples: millimeter millimeter millimeters millimeters, 1 entimeter millimeters millimeters or larger 987 Not appliable, in situ arinoma 988 Not appliable: Information not olleted for this ase 990 Miroinvasion Mirosopi fous or foi only; no depth given 998 No surgial speimen 999 Unknown, thikness not stated Lip, Upper CS Site-Speifi Fator 12 (Revised: 06/30/2008) Lip, Upper CS Site-Speifi Fator 13 (Revised: 06/30/2008) 29 April 2010 Part II - Lip - 21 Version

22 Lip, Upper CS Site-Speifi Fator 14 (Revised: 06/30/2008) Lip, Upper CS Site-Speifi Fator 15 (Revised: 06/30/2008) Lip, Upper CS Site-Speifi Fator 16 (Revised: 02/23/2009) Lip, Upper CS Site-Speifi Fator 17 (Revised: 02/23/2009) Lip, Upper CS Site-Speifi Fator 18 (Revised: 02/23/2009) Lip, Upper CS Site-Speifi Fator 19 (Revised: 02/23/2009) Lip, Upper CS Site-Speifi Fator 20 (Revised: 02/23/2009) 29 April 2010 Part II - Lip - 22 Version

23 Lip, Upper CS Site-Speifi Fator 21 (Revised: 02/23/2009) Lip, Upper CS Site-Speifi Fator 22 (Revised: 02/23/2009) Lip, Upper CS Site-Speifi Fator 23 (Revised: 02/23/2009) Lip, Upper CS Site-Speifi Fator 24 (Revised: 02/23/2009) Lip, Upper CS Site-Speifi Fator 25 (Revised: 02/23/2009) 29 April 2010 Part II - Lip - 23 Version

24 Malignant Melanoma of Upper Lip Lip (Vermilion or Labial Muosa) C00.0, C00.3 (M ) C00.0 External upper lip C00.3 Muosa of upper lip Note: AJCC inludes labial muosa (C00.3) with bual muosa (C06.0) CS Tumor Size CS Extension CS Tumor Size/Ext Eval CS Lymph Nodes CS Lymph Nodes Eval Reg LN Pos Reg LN Exam CS Mets at DX CS Mets Eval CS Site-Speifi Fator 1 Size of Lymph Nodes CS Site-Speifi Fator 2 OBSOLETE - Extraapsular Extension, Lymph Nodes for Head and Nek CS Site-Speifi Fator 3 Levels I-III, Lymph Nodes for Head and Nek CS Site-Speifi Fator 4 Levels IV-V and Retropharyngeal Lymph Nodes for Head and Nek CS Site-Speifi Fator 5 Levels VI-VII and Faial Lymph Nodes for Head and Nek CS Site-Speifi Fator 6 Parapharyngeal, Parotid, and Suboipital/Retroauriular Lymph Nodes, Lymph Nodes for Head and Nek CS Site-Speifi Fator 7 Upper and Lower Cervial Node Levels CS Site-Speifi Fator 8 Extraapsular Extension Clinially, Lymph Nodes for Head and Nek CS Site-Speifi Fator 9 Extraapsular Extension Pathologially, Lymph Nodes for Head and Nek CS Site-Speifi Fator 10 HPV (Human Papilloma Virus) Status CS Site-Speifi Fator 11 Measured Thikness (Depth) CS Site-Speifi Fator 12 CS Site-Speifi Fator 13 CS Site-Speifi Fator 14 CS Site-Speifi Fator 15 CS Site-Speifi Fator 16 CS Site-Speifi Fator 17 CS Site-Speifi Fator 18 CS Site-Speifi Fator 19 CS Site-Speifi Fator 20 CS Site-Speifi Fator 21 CS Site-Speifi Fator 22 CS Site-Speifi Fator 23 CS Site-Speifi Fator 24 CS Site-Speifi Fator 25 The following tables are available at the ollaborative staging website: Histology Inlusion Table AJCC 7th ed. Histology Exlusion Table AJCC 6th ed. AJCC TNM 7 Stage AJCC TNM 6 Stage Summary Stage 29 April 2010 Part II - Lip - 24 Version

25 Malignant Melanoma of Upper Lip CS Tumor Size (Revised: 02/03/2010) 000 No mass/tumor found millimeters (ode exat size in millimeters) millimeters or larger 990 Mirosopi fous or foi only and no size of fous given 991 Desribed as "less than 1 m" 992 Desribed as "less than 2 m," or "greater than 1 m," or "between 1 m and 2 m" 993 Desribed as "less than 3 m," or "greater than 2 m," or "between 2 m and 3 m" 994 Desribed as "less than 4 m," or "greater than 3 m," or "between 3 m and 4 m" 995 Desribed as "less than 5 m," or "greater than 4 m," or "between 4 m and 5 m" 999 Unknown; size not stated Malignant Melanoma of Upper Lip CS Extension (Revised: 01/04/2010) Note 1: AJCC does not inlude a Tis or TX ategory for melanoma of muosa of head and nek sites. Extension odes of 000 and 999 will be mapped to NA and AJCC stage group will be derived as NA. Note 2: AJCC does not inlude a T1 or T2 ategory for muosal melanoma of head and nek sites. Note 3: Use ode 300 for loalized tumor ONLY if no information is available to assign ode 105 or 470. Note 4: Use ode 470, 775, 810, or 815 if the physiian's assignment of T ategory is the ONLY information available about the extent of the tumor. TNM 7 TNM 6 SS77 SS In situ; noninvasive; intraepithelial NA NA IS IS 100 OBSOLETE DATA RETAINED V0200 ERROR NA L L Invasive tumor onfined to: Labial muosa (inner lip) Lamina propria Multiple foi Submuosa (superfiial invasion) Vermilion surfae Superfiial extension to: Skin of lip Subutaneous soft tissue of lip 105 Tumor onfined to muosa of upper lip: Labial muosa (inner lip) Vermilion surfae T3 NA L L 29 April 2010 Part II - Lip - 25 Version

26 TNM 7 TNM 6 SS77 SS OBSOLETE DATA CONVERTED V0200 See ode 520 ERROR ERROR ERROR ERROR Musulature 300 Loalized, NOS T3 NA L L 400 Extension via muosa to: Inner heek (bual muosa) Commissure Opposite (both) lip(s) 410 Extension via muosa to: Upper gingiva Gingiva NOS T3 NA RE RE T3 NA RE RE 440 Extension via muosa to lower gingiva T3 NA D RE 450 Extension via muosa to: Floor of mouth Tongue T3 NA D D 470 Stated as T3 with no other information on extension T3 NA L L 500 OBSOLETE DATA RETAINED V0200 ERROR NA RE RE Bual muosa (inner heek) Commissure Opposite (both) lip(s) 510 OBSOLETE DATA RETAINED V0200 ERROR NA RE RE Gingiva 520 Involvement of deep soft tissue or musulature of upper lip Soft tissue NOS (400 or 410) T4a NA L L T4a NA RE RE (Involvement of deep soft tissue or musulature of upper lip + Muosal involvement of any struture in ode 400 or 410) 540 Involvement of deep soft tissue or musulature of any struture in ode Involvement of deep tissue or periosteum of upper gingiva 700 Cartilage of maxilla Cartilage NOS Cortial bone of maxilla Cortial bone NOS Maxilla, NOS Bone NOS exept skull base T4a NA RE RE T4a NA RE RE T4a NA RE RE 29 April 2010 Part II - Lip - 26 Version

27 TNM 7 TNM 6 SS77 SS (520, 540, or 700) T4a NA D RE (Any struture in ode 520 or Muosa of lower gingiva) 710 Deep tissue or periosteum of lower gingiva T4a NA D RE 740 Skin of nose T4a NA RE D (440 or 710) T4a NA D D (Skin of nose + Muosa or deep tissue lower gingiva) 745 (520, 540, 700, 710, or 740) T4a NA D D (Any struture in ode 520, 540, 700, 710, or Muosa of floor of mouth or tongue) 748 Involvement of deep tissue or musulature of floor of mouth or tongue Inferior alveolar nerve 750 OBSOLETE DATA RETAINED V0200 T4a NA D D ERROR NA D D Tongue 755 Extrinsi musle of tongue Genioglossus Hyoglossus Palatoglossus Styloglossus T4a NA D D 760 Skin of fae/nek T4a NA D D 765 Cartilage of mandible Cortial bone of mandible Mandible NOS 770 OBSOLETE DATA RETAINED V0200 T4a NA D D ERROR NA D D Cartilage of mandible Cortial bone of mandible Floor of mouth Inferior alveolar nerve 775 Stated as T4a with no other information on extension T4a NA L L 790 Contiguous extension: Mastiator spae Pterygoid plates Skull base Internal arotid artery (enased) 800 OBSOLETE DATA RETAINED V0200 T4b NA D D ERROR NA D D Further ontiguous extension 29 April 2010 Part II - Lip - 27 Version

28 TNM 7 TNM 6 SS77 SS Further ontiguous extension: Brain Dura Lower ranial nerves (IX, X, XI, XII) Prevertebral spae Mediastinal strutures T4b NA D D 810 Stated as T4b with no other information on extension T4b NA D D 815 Stated as T4NOS with no other information on extension 950 OBSOLETE DATA RETAINED V0200 No evidene of primary tumor 999 Unknown extension Primary tumor annot be assessed T4NOS NA L L ERROR NA U U NA NA U U Malignant Melanoma of Upper Lip CS Tumor Size/Ext Eval (Revised: 11/13/2009) Staging Basis 7 Staging Basis 6 0 Does not meet riteria for AJCC pathologi staging: No surgial resetion done. Evaluation based on physial examination, imaging examination, or other non-invasive linial evidene. No autopsy evidene used. 1 Does not meet riteria for AJCC pathologi staging: No surgial resetion done. Evaluation based on endosopi examination, diagnosti biopsy, inluding fine needle aspiration biopsy, or other invasive tehniques, inluding surgial observation without biopsy. No autopsy evidene used. 2 Meets riteria for AJCC pathologi staging: p No surgial resetion done, but evidene derived from autopsy (tumor was suspeted or diagnosed prior to autopsy) 29 April 2010 Part II - Lip - 28 Version

29 Staging Basis 7 Staging Basis 6 3 Either riteria meets AJCC pathologi staging: p Surgial resetion performed WITHOUT pre-surgial systemi treatment or radiation OR surgial resetion performed, unknown if pre-surgial systemi treatment or radiation performed AND Evaluation based on evidene aquired before treatment, supplemented or modified by the additional evidene aquired during and from surgery, partiularly from pathologi examination of the reseted speimen. No surgial resetion done. Evaluation based on positive biopsy of highest T lassifiation. 5 Does not meet riteria for AJCC y-pathologi (yp) staging: Surgial resetion performed AFTER neoadjuvant therapy and tumor size/extension based on linial evidene, unless the pathologi evidene at surgery (AFTER neoadjuvant) is more extensive (see ode 6). 6 Meets riteria for AJCC y-pathologi (yp) staging: yp Surgial resetion performed AFTER neoadjuvant therapy AND tumor size/extension based on pathologi evidene, beause pathologi evidene at surgery is more extensive than linial evidene before treatment. 8 Meets riteria for autopsy (a) staging: a Evidene from autopsy only (tumor was unsuspeted or undiagnosed prior to autopsy) 9 Unknown if surgial resetion done Not assessed; annot be assessed Unknown if assessed Malignant Melanoma of Upper Lip CS Lymph Nodes (Revised: 12/26/2009) Note 1: For head and nek shemas, this field inludes all lymph nodes defined as Levels I-VII and Other by AJCC. The omplete definitions are provided in the General Instrutions. Note 2: For head and nek shemas, additional information about lymph nodes (size of involved nodes, extraapsular extension, levels involved, and loation of involved nodes above or below the lower border of the rioid artilage) is oded in Site-Speifi Fators 1, 3-9. Note 3: For head and nek aners, if lymph nodes are desribed only as "supralaviular", try to determine if they are in Level IV (deep to the sternoleidomastoid musle, in the lower jugular hain) or Level V (in the posterior triangle, inferior to the transverse ervial artery) and ode appropriately. If the speifi level annot be determined, onsider them as Level V nodes. TNM 7 TNM 6 SS77 SS None; no regional lymph node involvement N0 NA NONE NONE 29 April 2010 Part II - Lip - 29 Version

CS Tumor Size CS Extension CS Tumor Size/Ext Eval CS Lymph Nodes CS Lymph Nodes Eval Reg LN Pos Reg LN Exam CS Mets at DX CS Mets Eval

CS Tumor Size CS Extension CS Tumor Size/Ext Eval CS Lymph Nodes CS Lymph Nodes Eval Reg LN Pos Reg LN Exam CS Mets at DX CS Mets Eval Base of Tongue, Lingual Tonsil C01.9, C02.4 C01.9 Base of tongue, NOS C02.4 Lingual tonsil Note: AJCC inludes base of tongue (C01.9) with oropharynx (C10._). CS Tumor Size CS Extension CS Tumor Size/Ext

More information

CS Tumor Size CS Extension CS Tumor Size/Ext Eval CS Lymph Nodes CS Lymph Nodes Eval Reg LN Pos Reg LN Exam CS Mets at DX CS Mets Eval

CS Tumor Size CS Extension CS Tumor Size/Ext Eval CS Lymph Nodes CS Lymph Nodes Eval Reg LN Pos Reg LN Exam CS Mets at DX CS Mets Eval Floor of Mouth C04.0-C04.1, C04.8-C04.9 C04.0 Anterior floor of mouth C04.1 Lateral floor of mouth C04.8 Overlapping lesion of floor of mouth C04.9 Floor of mouth, NOS CS Tumor Size CS Extension CS Tumor

More information

KidneyParenchyma. Kidney (Renal Parenchyma)

KidneyParenchyma. Kidney (Renal Parenchyma) http://web2.fas.org/stage/kidneyparenhyma/shema.html for TNM 7 - Revised 01/21/2010 Kidney (Renal Parenhyma) C64.9 C64.9 Kidney, NOS (Renal parenhyma) Note: Laterality must be oded for this site. CS Tumor

More information

C15.0-C15.5, C15.8-C15.9

C15.0-C15.5, C15.8-C15.9 C15.0-C15.5, C15.8-C15.9 C15.0 Cervial esophagus C15.1 Thorai esophagus C15.2 Abdominal esophagus C15.3 Upper third of esophagus C15.4 Middle third of esophagus C15.5 Lower third of esophagus C15.8 Overlapping

More information

C15.0-C15.5, C15.8-C15.9

C15.0-C15.5, C15.8-C15.9 Esophagus C15.0-C15.5, C15.8-C15.9 C15.0 Cervial esophagus C15.1 Thorai esophagus C15.2 Abdominal esophagus C15.3 Upper third of esophagus C15.4 Middle third of esophagus C15.5 Lower third of esophagus

More information

Stomach CS Tumor Size (Revised: 06/30/2008)

Stomach CS Tumor Size (Revised: 06/30/2008) C16.1-C16.6, C16.8-C16.9 C16.1 Fundus of stomah C16.2 Body of stomah C16.3 Gastri antrum C16.4 Pylorus C16.5 Lesser urvature of stomah, NOS C16.6 Greater urvature of stomah, NOS C16.8 Overlapping lesion

More information

Nasal Cavity CS Tumor Size (Revised: 02/03/2010)

Nasal Cavity CS Tumor Size (Revised: 02/03/2010) Nasal Cavity C30.0 C30.0 Nasal cavity (excludes nose, NOS C76.0) Note: Laterality must be coded for this site, except subsites Nasal cartilage and Nasal septum, for which laterality is coded 0. CS Tumor

More information

Collaborative Stage for TNM 7 - Revised 12/02/2009 [ Schema ]

Collaborative Stage for TNM 7 - Revised 12/02/2009 [ Schema ] CS Tumor Size Collaborative Stage for TNM 7 - Revised 12/02/2009 [ Schema ] Note: the specific tumor size as documented in the medical record. If the ONLY information regarding tumor size is the physician's

More information

Collaborative Staging Manual and Coding Instructions Part II: Primary Site Schema

Collaborative Staging Manual and Coding Instructions Part II: Primary Site Schema C44.0-C44.9, C51.0-C51.2, C51.8-C51.9, C60.0-C60.2, C60.8-C60.9, C63.2 (M-8720-8790) C44.0 Skin of lip, NOS C44.1 Eyelid C44.2 External ear C44.3 Skin of ear and unspecified parts of face C44.4 Skin of

More information

Collaborative Stage for TNM 7 - Revised 07/14/2009 [ Schema ]

Collaborative Stage for TNM 7 - Revised 07/14/2009 [ Schema ] MelanomaSkin CS Tumor Size Collaborative Stage for TNM 7 - Revised 07/14/2009 [ Schema ] Code 000 No mass/tumor found Description 001-988 001-988 millimeters (code exact size in millimeters) 989 989 millimeters

More information

14. Mucosal Melanoma of the Head and Neck

14. Mucosal Melanoma of the Head and Neck 1 Terms of Use The cancer staging form is a specific document in the patient record; it is not a substitute for documentation of history, physical examination, and staging evaluation, or for documenting

More information

NAACCR Webinar Series 1

NAACCR Webinar Series 1 Collecting Cancer Data: Lip and Oral 2013 2014 NAACCR Webinar Series October 3, 2013 Q&A Please submit all questions concerning webinar content through the Q&A panel. Reminder: If you have participants

More information

AJCC Staging of Head & Neck Cancer (7 th edition, 2010) -LIP & ORAL CAVITY-

AJCC Staging of Head & Neck Cancer (7 th edition, 2010) -LIP & ORAL CAVITY- TX: primary tumor cannot be assessed T0: no evidence of primary tumor Tis: carcinoma in situ. T1: tumor is 2 cm or smaller AJCC Staging of Head & Neck Cancer (7 th edition, 2010) -LIP & ORAL CAVITY- T2:

More information

This form may provide more data elements than required for collection by standard setters such as NCI SEER, CDC NPCR, and CoC NCDB.

This form may provide more data elements than required for collection by standard setters such as NCI SEER, CDC NPCR, and CoC NCDB. 1 Terms of Use The cancer staging form is a specific document in the patient record; it is not a substitute for documentation of history, physical examination, and staging evaluation, or for documenting

More information

NAACCR Webinar Series

NAACCR Webinar Series NAACCR 2009-2010 Webinar Series Collecting Cancer Data: Lip & Oral Cavity 8/5/2010 Questions Please use the Q&A panel to submit your questions Send questions to All Panelist 2 Fabulous Prizes! NAACCR 2009/2010

More information

6. Cervical Lymph Nodes and Unknown Primary Tumors of the Head and Neck

6. Cervical Lymph Nodes and Unknown Primary Tumors of the Head and Neck 1 Terms of Use The cancer staging form is a specific document in the patient record; it is not a substitute for documentation of history, physical examination, and staging evaluation, or for documenting

More information

This form may provide more data elements than required for collection by standard setters such as NCI SEER, CDC NPCR, and CoC NCDB.

This form may provide more data elements than required for collection by standard setters such as NCI SEER, CDC NPCR, and CoC NCDB. 1 Terms of Use The cancer staging form is a specific document in the patient record; it is not a substitute for documentation of history, physical examination, and staging evaluation, or for documenting

More information

Collaborative Stage for TNM 7 - Revised 06/30/2008 [ Schema ]

Collaborative Stage for TNM 7 - Revised 06/30/2008 [ Schema ] Collaborative Stage for TNM 7 - Revised 06/30/2008 [ Schema ] CS Tumor Size 000 No mass/tumor found 001-988 001-988 millimeters (code exact size in millimeters) 989 989 millimeters or larger 990 Microscopic

More information

(loco-regional disease)

(loco-regional disease) (loco-regional disease) (oral cavity) (circumvillae papillae) (subsite) A (upper & lower lips) B (buccal membrane) C (mouth floor) D (upper & lower gingiva) E (hard palate) F (tongue -- anterior 2/3 rds

More information

EVERYTHING YOU WANTED TO KNOW ABOUT. Robin Billet, MA, CTR, Head & Neck CTAP Member May 9, 2013

EVERYTHING YOU WANTED TO KNOW ABOUT. Robin Billet, MA, CTR, Head & Neck CTAP Member May 9, 2013 EVERYTHING YOU WANTED TO KNOW ABOUT. Robin Billet, MA, CTR, Head & Neck CTAP Member May 9, 2013 Head and Neck Coding and Staging Head and Neck Coding and Staging Anatomy & Primary Site Sequencing and MPH

More information

Exercise 15: CSv2 Data Item Coding Instructions ANSWERS

Exercise 15: CSv2 Data Item Coding Instructions ANSWERS Exercise 15: CSv2 Data Item Coding Instructions ANSWERS CS Tumor Size Tumor size is the diameter of the tumor, not the depth or thickness of the tumor. Chest x-ray shows 3.5 cm mass; the pathology report

More information

10. HPV-Mediated (p16+) Oropharyngeal Cancer

10. HPV-Mediated (p16+) Oropharyngeal Cancer 1 Terms of Use The cancer staging form is a specific document in the patient record; it is not a substitute for documentation of history, physical examination, and staging evaluation, or for documenting

More information

Thyroid INTRODUCTION ANATOMY SUMMARY OF CHANGES

Thyroid INTRODUCTION ANATOMY SUMMARY OF CHANGES AJC 7/14/06 1:19 PM Page 67 Thyroid C73.9 Thyroid gland SUMMARY OF CHANGES Tumor staging (T) has been revised and the categories redefined. T4 is now divided into T4a and T4b. Nodal staging (N) has been

More information

NAACCR Webinar Series 1. Instructors Q&A 10/6/2011. Collecting Cancer Data: Larynx Including Mucosal Melanoma of Larynx.

NAACCR Webinar Series 1. Instructors Q&A 10/6/2011. Collecting Cancer Data: Larynx Including Mucosal Melanoma of Larynx. NAACCR 2011 2012 Webinar Series Collecting Cancer Data: Larynx Instructors Shannon Vann, CTR Jim Hofferkamp, CTR 2 Q&A Please submit all questions concerning webinar content through the Q&A panel. 3 NAACCR

More information

Q&A. Fabulous Prizes. Collecting Cancer Data: Pharynx 12/6/12. NAACCR Webinar Series Collecting Cancer Data Pharynx

Q&A. Fabulous Prizes. Collecting Cancer Data: Pharynx 12/6/12. NAACCR Webinar Series Collecting Cancer Data Pharynx Collecting Cancer Data Pharynx NAACCR 2012 2013 Webinar Series Q&A Please submit all questions concerning webinar content through the Q&A panel. Reminder: If you have participants watching this webinar

More information

NAACCR Hospital Registry Webinar Series

NAACCR Hospital Registry Webinar Series NAACCR Hospital Registry Webinar Series Shannon Vann, CTR Jim Hofferkamp, CTR Webinar Series 1 Abstracting Thyroid Cancer Incidence & Image source: Thyroid ABC Health and Well Being Webinar Series 2 Anatomy

More information

CS Tumor Size CS Extension CS Tumor Size/Ext Eval CS Lymph Nodes CS Lymph Nodes Eval Reg LN Pos Reg LN Exam CS Mets at DX CS Mets Eval

CS Tumor Size CS Extension CS Tumor Size/Ext Eval CS Lymph Nodes CS Lymph Nodes Eval Reg LN Pos Reg LN Exam CS Mets at DX CS Mets Eval C70.0, C71.0-C71.9 C70.0 Cerebral meninges C71.0 Cerebrum C71.1 Frontal lobe C71.2 Temporal lobe C71.3 Parietal lobe C71.4 Occipital lobe C71.5 Ventricle, NOS C71.6 Cerebellum, NOS C71.7 Brain stem C71.8

More information

L ARYNX S TAGING F ORM

L ARYNX S TAGING F ORM CLI N I CA L Extent of disease before any treatment y clinical staging completed after neoadjuvant therapy but before subsequent surgery TX T0 Tis a b L ARYNX S TAGING F ORM LATERALITY: TUMOR SIZE: left

More information

AJCC Cancer Staging 8 th edition. Lip and Oral Cavity Oropharynx (p16 -) and Hypopharynx Larynx

AJCC Cancer Staging 8 th edition. Lip and Oral Cavity Oropharynx (p16 -) and Hypopharynx Larynx AJCC Cancer Staging 8 th edition Lip and Oral Cavity Oropharynx (p16 -) and Hypopharynx Larynx AJCC 7 th edition Lip and Oral cavity Pharynx Larynx KEY CHANGES Skin of head and neck (Vermilion of the lip)

More information

Case Scenario 1. 7/13/12 Anterior floor of mouth biopsy: Infiltrating squamous cell carcinoma, not completely excised.

Case Scenario 1. 7/13/12 Anterior floor of mouth biopsy: Infiltrating squamous cell carcinoma, not completely excised. Case Scenario 1 7/5/12 History A 51 year old white female presents with a sore area on the floor of her mouth. She claims the area has been sore for several months. She is a current smoker and user of

More information

Head & Neck Case # 1

Head & Neck Case # 1 DISCHARGE SUMMARY Head & Neck Case # 1 Date of Admission: 10/30/2010 Date of Discharge: 11/02/2010 Present Medical History: The patient is a 33-year-old lady with a history of right superior alveolar ridge

More information

Head & Neck Clinical Sub Group. Network Agreed Imaging Guidelines for UAT and Thyroid Cancer. Measure Nos: 11-1C-105i & 11-1C-106i

Head & Neck Clinical Sub Group. Network Agreed Imaging Guidelines for UAT and Thyroid Cancer. Measure Nos: 11-1C-105i & 11-1C-106i Greater Manchester, Lancashire & South Cumbria Strategic Clinical Network & Senate Head & Neck Clinical Sub Group Network Agreed Imaging Guidelines for UAT and Thyroid Cancer Measure Nos: 11-1C-105i &

More information

Oral cancer: Prognosis & Treatment. Dr. Hani Al Sheikh Radhi

Oral cancer: Prognosis & Treatment. Dr. Hani Al Sheikh Radhi Oral cancer: Prognosis & Treatment Dr. Hani Al Sheikh Radhi Prognostic factors in Oral caner TNM staging T stage N stage M stage Site Histological Factors Vascular & Perineural Invasion Surgical Margins

More information

47. Melanoma of the Skin

47. Melanoma of the Skin 1 Terms of Use The cancer staging form is a specific document in the patient record; it is not a substitute for documentation of history, physical examination, and staging evaluation, or for documenting

More information

Case Scenario. 7/13/12 Anterior floor of mouth biopsy: Infiltrating squamous cell carcinoma, not completely excised.

Case Scenario. 7/13/12 Anterior floor of mouth biopsy: Infiltrating squamous cell carcinoma, not completely excised. Case Scenario 7/5/12 History A 51 year old white female presents with a sore area on the floor of her mouth. She claims the area has been sore for several months. She is a current smoker and user of alcohol.

More information

Head and Neck Tumours

Head and Neck Tumours Head and Neck Tumours Introductory Notes The following sites are included: Lip, oral cavity Pharynx: oropharynx, nasopharynx, hypopharynx Larynx: supraglottis, glottis, subglottis Nasal cavity and paranasal

More information

LYMPHATIC DRAINAGE IN THE HEAD & NECK

LYMPHATIC DRAINAGE IN THE HEAD & NECK LYMPHATIC DRAINAGE IN THE HEAD & NECK Like other parts of the body, the head and neck contains lymph nodes (commonly called glands). Which form part of the overall Lymphatic Drainage system of the body.

More information

Thyroid and Adrenal Gland

Thyroid and Adrenal Gland Thyroid and Adrenal Gland NAACCR 2011 2012 Webinar Series 12/1/11 Q&A Please submit all questions concerning webinar content through the Q&A panel. Reminder: If you have participants watching this webinar

More information

Basic Anatomy and Physiology of the Lips and Oral Cavity. Dr. Faghih

Basic Anatomy and Physiology of the Lips and Oral Cavity. Dr. Faghih Basic Anatomy and Physiology of the Lips and Oral Cavity Dr. Faghih It is divided into seven specific subsites : 1. Lips 2. dentoalveolar ridges 3. oral tongue 4. retromolar trigone 5. floor of mouth 6.

More information

CERVICAL LYMPH NODES

CERVICAL LYMPH NODES CERVICAL LYMPH NODES (ANATOMY & EXAMINATION) Hemant (DTCD 1 st YEAR) 1. Lymphatic Tissues: A Type of connective tissue that contains large numbers of lymphocytes. 2. Lymphatic Vessels: Are Tubes that assist

More information

Case Scenario 1. Pathology: Specimen type: Incisional biopsy of the glottis Histology: Moderately differentiated squamous cell carcinoma

Case Scenario 1. Pathology: Specimen type: Incisional biopsy of the glottis Histology: Moderately differentiated squamous cell carcinoma Case Scenario 1 History A 52 year old male with a 20 pack year smoking history presented with about a 6 month history of persistent hoarseness. The patient had a squamous cell carcinoma of the lip removed

More information

46. Merkel Cell Carcinoma

46. Merkel Cell Carcinoma 1 Terms of Use The cancer staging form is a specific document in the patient record; it is not a substitute for documentation of history, physical examination, and staging evaluation, or for documenting

More information

ACOS Inquiry and Response Selected Inquires CS Tumor Size/Extension Evaluation, CS Lymph Nodes Evaluation, CS Metastasis at Diagnosis Evaluation *

ACOS Inquiry and Response Selected Inquires CS Tumor Size/Extension Evaluation, CS Lymph Nodes Evaluation, CS Metastasis at Diagnosis Evaluation * ACOS Inquiry and Response Selected Inquires CS Tumor Size/Extension Evaluation, CS Lymph Nodes Evaluation, CS Metastasis at Diagnosis Evaluation * CS Tumor Size/Extension Evaluation 24842 12/11/2007: Q:

More information

ANTERIOR CERVICAL TRIANGLE (Fig. 2.1 )

ANTERIOR CERVICAL TRIANGLE (Fig. 2.1 ) 2 Neck Anatomy ANTERIOR CERVICAL TRIANGLE (Fig. 2.1 ) The boundaries are: Lateral: sternocleidomastoid muscle Superior: inferior border of the mandible Medial: anterior midline of the neck This large triangle

More information

Esophagus Stomach 4/2/15

Esophagus Stomach 4/2/15 Collecting Cancer Data: Larynx & Thyroid 2014-2015 NAACCR Webinar Series May 7, 2015 Q&A Please submit all questions concerning webinar content through the Q&A panel. Reminder: If you have participants

More information

Compartmentalization of the larynx Sites and subsites Supraglottis Glottis subglottis Spaces Pre-epiglottic epiglottic space Para-glottic space

Compartmentalization of the larynx Sites and subsites Supraglottis Glottis subglottis Spaces Pre-epiglottic epiglottic space Para-glottic space Stroboscopy Rounds February 8, 2008 C. Matt Stewart, M.D.,Ph.D. Compartmentalization of the larynx Sites and subsites Supraglottis Glottis subglottis Spaces Pre-epiglottic epiglottic space Para-glottic

More information

Case Scenario 1 Worksheet. Primary Site C44.4 Morphology 8743/3 Laterality 0 Stage/ Prognostic Factors

Case Scenario 1 Worksheet. Primary Site C44.4 Morphology 8743/3 Laterality 0 Stage/ Prognostic Factors CASE SCENARIO 1 9/10/13 HISTORY: Patient is a 67-year-old white male and presents with lesion located 4-5cm above his right ear. The lesion has been present for years. No lymphadenopathy. 9/10/13 anterior

More information

NAACCR Webinar Series 11/2/2017

NAACCR Webinar Series 11/2/2017 COLLECTING CANCER DATA: LARYNX 2017 2018 NAACCR WEBINAR SERIES Q&A Please submit all questions concerning webinar content through the Q&A panel. Reminder: If you have participants watching this webinar

More information

Completing the Puzzle AJCC TNM Staging Breast. Nicole Catlett, CTR 2017 Kentucky Cancer Registry Fall Conference, September 21 & 22, 2017

Completing the Puzzle AJCC TNM Staging Breast. Nicole Catlett, CTR 2017 Kentucky Cancer Registry Fall Conference, September 21 & 22, 2017 Completing the Puzzle AJCC TNM Staging Breast Nicole Catlett, CTR 2017 Kentucky Cancer Registry Fall Conference, September 21 & 22, 2017 OBJECTIVES Understanding of Breast TNM staging Identify clinical

More information

Case Scenario 1. The patient has now completed his neoadjuvant chemoradiation and has been cleared for surgery.

Case Scenario 1. The patient has now completed his neoadjuvant chemoradiation and has been cleared for surgery. Case Scenario 1 July 10, 2010 A 67-year-old male with squamous cell carcinoma of the mid thoracic esophagus presents for surgical resection. The patient has completed preoperative chemoradiation. This

More information

Case Scenario #1 Larynx

Case Scenario #1 Larynx Case Scenario #1 Larynx 56 year old white female who presented with a 2 month history of hoarseness treated with antibiotics, but with no improvement. In the last 3 weeks, she has had a 15 lb weight loss,

More information

Collaborative Stage. Site-Specific Instructions - LUNG

Collaborative Stage. Site-Specific Instructions - LUNG Slide 1 Collaborative Stage Site-Specific Instructions - LUNG In this presentation, we are going to review the AJCC Cancer Staging criteria for the lung primary site. Slide 2 Reading Assignments As each

More information

Evaluation and Treatment of Dysphagia in the Head and Neck Cancer Patient

Evaluation and Treatment of Dysphagia in the Head and Neck Cancer Patient Evaluation and Treatment of Dysphagia in the Head and Neck Cancer Patient Linda Stachowiak MS/CCCSLP BCS-S Speech Pathology Oncology Specialist UFHealth Cancer Center at Orlando Health Orlando Florida

More information

STAGE CATEGORY DEFINITIONS

STAGE CATEGORY DEFINITIONS CLINICAL Extent of disease before any treatment y clinical staging completed after neoadjuvant therapy but before subsequent surgery TX Tis Tis (DCIS) Tis (LCIS) Tis (Paget s) T1 T1mi T1a T1b T1c a b c

More information

Chapter 2 Staging of Breast Cancer

Chapter 2 Staging of Breast Cancer Chapter 2 Staging of Breast Cancer Zeynep Ozsaran and Senem Demirci Alanyalı 2.1 Introduction Five decades ago, Denoix et al. proposed classification system (tumor node metastasis [TNM]) based on the dissemination

More information

Q&A. Overview. Collecting Cancer Data: Prostate. Collecting Cancer Data: Prostate 5/5/2011. NAACCR Webinar Series 1

Q&A. Overview. Collecting Cancer Data: Prostate. Collecting Cancer Data: Prostate 5/5/2011. NAACCR Webinar Series 1 Collecting Cancer Data: Prostate NAACCR 2010-2011 Webinar Series May 5, 2011 Q&A Please submit all questions concerning webinar content through the Q&A panel Overview NAACCR 2010-2011 Webinar Series 1

More information

Head & Neck Contouring

Head & Neck Contouring Head & Neck Contouring Presented by James Wheeler, MD Center for Cancer Care Goshen, IN 46526 September 12, 2014 Special Thanks to: Spencer Boulter, Director of Operations (AAMD) Adam Moore, RT(T), CMD

More information

4/10/2018. SEER EOD and Summary Stage. Overview KCR 2018 SPRING TRAINING. What is SEER EOD? Ambiguous Terminology General Guidelines

4/10/2018. SEER EOD and Summary Stage. Overview KCR 2018 SPRING TRAINING. What is SEER EOD? Ambiguous Terminology General Guidelines SEER EOD and Summary Stage KCR 2018 SPRING TRAINING Overview What is SEER EOD Ambiguous Terminology General Guidelines EOD Primary Tumor EOD Regional Nodes EOD Mets SEER Summary Stage 2018 Site Specific

More information

The Neck the lower margin of the mandible above the suprasternal notch and the upper border of the clavicle

The Neck the lower margin of the mandible above the suprasternal notch and the upper border of the clavicle The Neck is the region of the body that lies between the lower margin of the mandible above and the suprasternal notch and the upper border of the clavicle below Nerves of the neck Cervical Plexus Is formed

More information

QUIZZES WITH ANSWERS FOR COLLECTING CANCER DATA: PHARYNX

QUIZZES WITH ANSWERS FOR COLLECTING CANCER DATA: PHARYNX QUIZZES WITH ANSWERS FOR COLLECTING CANCER DATA: PHARYNX MP/H Quiz 1. A patient presented with a prior history of squamous cell carcinoma of the base of the tongue. The malignancy was originally diagnosed

More information

Carcinoma of the Urinary Bladder Histopathology

Carcinoma of the Urinary Bladder Histopathology Carcinoma of the Urinary Bladder Histopathology Reporting Proforma (Radical & Partial Cystectomy, Cystoprostatectomy) Includes the International Collaboration on Cancer reporting dataset denoted by * Family

More information

Since the first description of the radical neck dissection by George Crile almost a century

Since the first description of the radical neck dissection by George Crile almost a century ORIGINAL ARTICLE Neck Dissection Classification Update Revisions Proposed by the American Head and Neck Society and the American Academy of Otolaryngology Head and Neck Surgery K. Thomas Robbins, MD; Garry

More information

What s New for 8 th Edition

What s New for 8 th Edition What s New for 8 th Edition KCR 2018 SPRING TRAINING Overview What s New New Chapters for 8 th Editions Chapters That Split in 8 th Edition Merged 8 th Edition Chapters Blanks vs Xs How to Navigate Through

More information

Carcinoma of the Renal Pelvis and Ureter Histopathology

Carcinoma of the Renal Pelvis and Ureter Histopathology Carcinoma of the Renal Pelvis and Ureter Histopathology Reporting Proforma (NEPHROURETERECTOMY AND URETERECTOMY) Includes the International Collaboration on Cancer reporting dataset denoted by * Family

More information

Neck-2. Dr. Heba Kalbouneh Associate Professor of Anatomy and Histology

Neck-2. Dr. Heba Kalbouneh Associate Professor of Anatomy and Histology Neck-2 ` Dr. Heba Kalbouneh Associate Professor of Anatomy and Histology Triangles of the neck Side of the neck Midline Lower border of mandible Line between angle of mandible and mastoid Superior nuchal

More information

Lecture 07. Lymphatic's of Head & Neck. By: Dr Farooq Amanullah Khan PMC

Lecture 07. Lymphatic's of Head & Neck. By: Dr Farooq Amanullah Khan PMC Lecture 07 Lymphatic's of Head & Neck By: Dr Farooq Amanullah Khan PMC Dated: 28.11.2017 Lymphatic Vessels Of the 800 lymph nodes in the human body, 300 are in the Head & neck region. The lymphatic vessels

More information

QUIZZES WITH ANSWERS FOR COLLECTING CANCER DATA: PHARYNX

QUIZZES WITH ANSWERS FOR COLLECTING CANCER DATA: PHARYNX QUIZZES WITH ANSWERS FOR COLLECTING CANCER DATA: PHARYNX MP/H Quiz 1. A patient presented with a prior history of squamous cell carcinoma of the base of the tongue. The malignancy was originally diagnosed

More information

CANCER REPORTING IN CALIFORNIA: ABSTRACTING AND CODING PROCEDURES California Cancer Reporting System Standards, Volume I

CANCER REPORTING IN CALIFORNIA: ABSTRACTING AND CODING PROCEDURES California Cancer Reporting System Standards, Volume I CANCER REPORTING IN CALIFORNIA: ABSTRACTING AND CODING PROCEDURES California Cancer Reporting System Standards, Volume I Changes and Clarifications 16 th Edition April 15, 2016 Quick Look- Updates to Volume

More information

FINE NEEDLE ASPIRATION OF ENLARGED LYMPH NODE: Metastatic squamous cell carcinoma

FINE NEEDLE ASPIRATION OF ENLARGED LYMPH NODE: Metastatic squamous cell carcinoma Case Scenario 1 HNP: A 70 year old white male presents with dysphagia. The patient is a current smoker, current user of alcohol and is HPV positive. A CT of the Neck showed mass in the left pyriform sinus.

More information

INTRODUCTION TO CANCER STAGING

INTRODUCTION TO CANCER STAGING INTRODUCTION TO CANCER STAGING Patravoot Vatanasapt, MD Dept. Otorhinolaryngology Khon Kaen Cancer Registry Faculty of Medicine Khon Kaen University THAILAND Staging is the attempt to assess the size

More information

Dissection and reporting of the organs of the female genital tract

Dissection and reporting of the organs of the female genital tract Correspondene to: Mark K Heatley, Department of Histopathology, St James University Hospital, Bekett Street, Leeds, West Yorkshire LS9 7TF, UK Aepted 15 August 2007 Published Online First 7 September 2007

More information

11/21/13 CEA: 1.7 WNL

11/21/13 CEA: 1.7 WNL Case Scenario 1 A 70 year-old white male presented to his primary care physician with a recent history of rectal bleeding. He was referred for imaging and a colonoscopy and was found to have adenocarcinoma.

More information

Collaborative Stage Site-Specific Instructions - BREAST

Collaborative Stage Site-Specific Instructions - BREAST Slide 1 Collaborative Stage Site-Specific Instructions - BREAST In this presentation, we are going to review the CS Data Items and coding instructions for the breast primary site. Slide 2 Reading Assignments

More information

Q: How do you clinically code the N if the nodes are stated to be positive on mammogram/us or other imaging? No biopsy of nodes was done.

Q: How do you clinically code the N if the nodes are stated to be positive on mammogram/us or other imaging? No biopsy of nodes was done. Q&A Breast Webinar Q: One of my investigators is interested in knowing when Oncotype DX data collection was implemented. That data is collected in SSFs 22 and 23. I remember that the SSFs for breast were

More information

6 th Reprint Handbook Pages AJCC 7 th Edition

6 th Reprint Handbook Pages AJCC 7 th Edition 6 th Reprint Handbook Pages AJCC 7 th Edition AJCC 7 th Edition Errata for 6 th Reprint Table 1 Handbook No Significant Staging Clarifications for 6 th Reprint AJCC 7 th Edition Errata for 6 th Reprint

More information

Temporal fossa Infratemporal fossa Pterygopalatine fossa Terminal branches of external carotid artery Pterygoid venous plexus

Temporal fossa Infratemporal fossa Pterygopalatine fossa Terminal branches of external carotid artery Pterygoid venous plexus Outline of content Temporal fossa Infratemporal fossa Pterygopalatine fossa Terminal branches of external carotid artery Pterygoid venous plexus Boundary Content Communication Mandibular division of trigeminal

More information

Case Scenario 1 History and Physical 3/15/13 Imaging Pathology

Case Scenario 1 History and Physical 3/15/13 Imaging Pathology Case Scenario 1 History and Physical 3/15/13 The patient is an 84 year old white female who presented with an abnormal mammogram. The patient has a five year history of refractory anemia with ringed sideroblasts

More information

AJCC Cancer Staging Form Supplement

AJCC Cancer Staging Form Supplement AJCC Cancer Staging Form Supplement AJCC Cancer Staging Manual, Eighth Edition Last updated 05 June 2018 AMERICAN JOINT COMMITTEE ON CANCER Executive Office 633 North Saint Clair Street Chicago, IL 60611

More information

Management of Salivary Gland Malignancies. No Disclosures or Conflicts of Interest. Anatomy 10/4/2013

Management of Salivary Gland Malignancies. No Disclosures or Conflicts of Interest. Anatomy 10/4/2013 Management of Salivary Gland Malignancies Daniel G. Deschler, MD Director: Division of Head and Neck Surgery Massachusetts Eye & Ear Infirmary Massachusetts General Hospital Professor Harvard Medical School

More information

Multifocal Carcinoma of Oral Cavity: A Case Report

Multifocal Carcinoma of Oral Cavity: A Case Report JKIMSU, Vol. 5, No. 1, January-Marh, 2016 ISSN 2231-4261 CASE REPORT Multifoal Carinoma of Oral Cavity: A Case Report 1* 2 Anilkumar L Bhoweer, Sudarshan Ranpise 1 Consultant Oral Mediine & Dental Radiology

More information

Primary Cutaneous Melanoma Pathology Reporting Proforma DD MM YYYY. *Tumour site. *Specimen laterality. *Specimen type

Primary Cutaneous Melanoma Pathology Reporting Proforma DD MM YYYY. *Tumour site. *Specimen laterality. *Specimen type Primary Cutaneous Melanoma Pathology Reporting Proforma Includes the International Collaboration on Cancer reporting dataset denoted by * Family name Given name(s) Date of birth DD MM YYYY Sex Male Female

More information

Oral cavity : consist of two parts: the oral vestibule and the oral cavity proper. Oral vestibule : is slit like space between.

Oral cavity : consist of two parts: the oral vestibule and the oral cavity proper. Oral vestibule : is slit like space between. Oral cavity Oral cavity : consist of two parts: the oral vestibule and the oral cavity proper Oral vestibule : is slit like space between the teeth, buccal gingiva, lips, and cheeks 1 Oral cavity Oral

More information

Alexander C Vlantis. Selective Neck Dissection 33

Alexander C Vlantis. Selective Neck Dissection 33 05 Modified Radical Neck Dissection Type II Alexander C Vlantis Selective Neck Dissection 33 Modified Radical Neck Dissection Type II INCISION Various incisions can be used for a neck dissection. The incision

More information

The following images were all acquired using a CTI Biograph

The following images were all acquired using a CTI Biograph Positron Emission Tomography/ Computed Tomography Imaging of Head and Neck Tumors: An Atlas Michael M. Graham, MD, PhD, and Yusuf Menda, MD Department of Radiology, University of Iowa, Iowa City, IA. Address

More information

Olfactory Neuroblastoma: MR Evaluation

Olfactory Neuroblastoma: MR Evaluation Olfatory Neuroblastoma: MR Evaluation Cheng Li,I.2.3 David M. Yousem,I.2.3 Rihard E. Hayden,2 and Rihard L. Dotyl.2 PURPOSE: To evaluate MR in the diagnosis and staging of olfatory neuroblastoma. METHODS:

More information

UICC TNM 8 th Edition Errata

UICC TNM 8 th Edition Errata UICC TNM 8 th Edition Errata ions are in italics Page 28 Oropharynx p16 positive Pathological Stage II,T2 N2 M0 T3 N0,N1 M0 Stage II,T2 N2 M0 T3,T4 N0,N1 M0 Page 61 Oesophagus Adenocarcinoma Pathological

More information

Descriptor Definition Author s notes TNM descriptors Required only if applicable; select all that apply multiple foci of invasive carcinoma

Descriptor Definition Author s notes TNM descriptors Required only if applicable; select all that apply multiple foci of invasive carcinoma S5.01 The tumour stage and stage grouping must be recorded to the extent possible, based on the AJCC Cancer Staging Manual (7 th Edition). 11 (See Tables S5.01a and S5.01b below.) Table S5.01a AJCC breast

More information

Dissection and reporting of the organs of the female genital tract

Dissection and reporting of the organs of the female genital tract Correspondene to: Mark K Heatley, Department of Histopathology, St James University Hospital, Bekett Street, Leeds, West Yorkshire LS9 7TF, UK Aepted 15 August 2007 Published Online First 7 September 2007

More information

Veins of the Face and the Neck

Veins of the Face and the Neck Veins of the Face and the Neck Facial Vein The facial vein is formed at the medial angle of the eye by the union of the supraorbital and supratrochlear veins. connected through the ophthalmic veins with

More information

CS Evaluation Fields. Outline of Presentation. Purpose of Evaluation Field. CSv2 Title of Presentation Jan 2011 Lecture Version: 1.

CS Evaluation Fields. Outline of Presentation. Purpose of Evaluation Field. CSv2 Title of Presentation Jan 2011 Lecture Version: 1. CS Evaluation Fields Education and Training Team Collaborative Stage Data Collection System Version 02.03.02 (Effective date: 1/1/2011) Outline of Presentation Purpose AJCC TNM Classification Eval data

More information

Case Scenario 1: This case has been slightly modified from the case presented during the live session to add clarity.

Case Scenario 1: This case has been slightly modified from the case presented during the live session to add clarity. Case Scenario 1: This case has been slightly modified from the case presented during the live session to add clarity. Background: 46 year old married premenopausal female with dense breasts has noticed

More information

Head & Neck Staging. Donna M. Gress, RHIT, CTR Technical Editor, AJCC Cancer Staging Manual First Author, Chapter 1: Principles of Cancer Staging

Head & Neck Staging. Donna M. Gress, RHIT, CTR Technical Editor, AJCC Cancer Staging Manual First Author, Chapter 1: Principles of Cancer Staging AJCC 8 th Edition Staging Head & Neck Staging Donna M. Gress, RHIT, CTR Technical Editor, AJCC Cancer Staging Manual First Author, Chapter 1: Principles of Cancer Staging Validating science. Improving

More information

Gastric Cancer Histopathology Reporting Proforma

Gastric Cancer Histopathology Reporting Proforma Gastric Cancer Histopathology Reporting Proforma Mandatory questions (i.e. protocol standards) are in bold (e.g. S1.01). S1.01 Identification Family name Given name(s) Date of birth Sex Male Female Intersex/indeterminate

More information

Physician to Physician AJCC 8 th Edition. Head and Neck. Summary of Changes. AJCC Cancer Staging Manual, 7 th Ed. Head and Neck Chapters

Physician to Physician AJCC 8 th Edition. Head and Neck. Summary of Changes. AJCC Cancer Staging Manual, 7 th Ed. Head and Neck Chapters Physician to Physician Head and Neck William M. Lydiatt, MD Chair of Surgery Nebraska Methodist Hospital Clinical Professor of Surgery, Creighton University Validating science. Improving patient care.

More information

AJCC 8 th Edition Staging. Head & Neck Staging. Learning Objectives. This webinar is sponsored by. the Centers for Disease Control and Prevention.

AJCC 8 th Edition Staging. Head & Neck Staging. Learning Objectives. This webinar is sponsored by. the Centers for Disease Control and Prevention. AJCC 8 th Edition Staging Head & Neck Staging Donna M. Gress, RHIT, CTR Technical Editor, AJCC Cancer Staging Manual First Author, Chapter 1: Principles of Cancer Staging Validating science. Improving

More information

Every Flex is Quite Complex

Every Flex is Quite Complex Name Class Date Every Flex is Quite Complex Struture and Funtion in a Chiken Wing Investigative Lab 27 8 Question How do the tissues of a hiken wing work together during movement? Lab Overview In this

More information

40 TH EUROPEAN CONGRESS 0F CYTOLOGY LIVERPOOL, UK October 2-5, 2016

40 TH EUROPEAN CONGRESS 0F CYTOLOGY LIVERPOOL, UK October 2-5, 2016 Outcomes from the diagnostic approach of thyroid lesions using US-FNA and LBC in clinical practice Emmanouel Mastorakis MD PhD Cytopathologist Director in Cytopathology Laboratory Regional General Hospital

More information

Cervical Lymph Nodes

Cervical Lymph Nodes Cervical Lymph Nodes Diana Gaitini, MD Unit of Ultrasound, Department of Medical Imaging Rambam Medical Center and Faculty of Medicine Technion, Israel Institute of Technology Haifa, Israel Learning Targets

More information

Protocol for the Examination of Specimens from Patients with Carcinomas of the Lip and Oral Cavity

Protocol for the Examination of Specimens from Patients with Carcinomas of the Lip and Oral Cavity Protocol for the Examination of Specimens from Patients with Carcinomas of the Lip and Oral Cavity Protocol applies to all invasive carcinomas of the oral cavity, including lip and tongue. Mucosal malignant

More information